QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-evolent-health-lowers-price-target-to-7

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:EVH) with a Overweight and lowers the price target from $13 to $7.

 canaccord-genuity-maintains-buy-on-evolent-health-lowers-price-target-to-9

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 ...

 bmo-capital-initiates-coverage-on-evolent-health-with-outperform-rating-announces-price-target-of-7

BMO Capital analyst Sean Dodge initiates coverage on Evolent Health (NYSE:EVH) with a Outperform rating and announces Price ...

 oppenheimer-maintains-outperform-on-evolent-health-lowers-price-target-to-12

Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target fro...

 truist-securities-maintains-buy-on-evolent-health-lowers-price-target-to-10

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $1...

 citizens-maintains-market-outperform-on-evolent-health-lowers-price-target-to-11

Citizens analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price targe...

 btig-maintains-buy-on-evolent-health-lowers-price-target-to-16

BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $20 to $16.

 evolent-health-american-oncology-network-announce-new-model-to-enhance-cancer-care

Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and...

 evolent-health-raises-fy2025-sales-guidance-from-1850b-1880b-to-1870b-1880b-vs-1884b-est

Evolent Health (NYSE:EVH) raises FY2025 sales outlook from $1.850 billion-$1.880 billion to $1.870 billion-$1.880 billion vs $1...

 evolent-health-sees-q4-sales-462000m-472000m-vs-481406m-est

Evolent Health (NYSE:EVH) sees Q4 sales of $462.000 million-$472.000 million vs $481.406 million analyst estimate.

 evolent-health-q3-adj-eps-005-misses-011-estimate-sales-479533m-beat-473745m-estimate

Evolent Health (NYSE:EVH) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.11 b...

 btig-reiterates-buy-on-evolent-health-maintains-20-price-target

BTIG analyst David Larsen reiterates Evolent Health (NYSE:EVH) with a Buy and maintains $20 price target.

 privia-health-acquires-evolents-aco-business-to-boost-value-based-care

Privia Health (PRVA) to acquire Evolent Health's (EVH) ACO business for $100M, expanding its value-based care footprint.

 stephens--co-reiterates-equal-weight-on-evolent-health-maintains-9-price-target

Stephens & Co. analyst Jeff Garro reiterates Evolent Health (NYSE:EVH) with a Equal-Weight and maintains $9 price target.

 evolent-health-affirms-q3-sales-guidance-of-460000m-480000m-vs-473745m-est

Evolent Health (NYSE:EVH) affirms Q3 sales outlook from $460.000 million-$480.000 million to $460.000 million-$480.000 million ...

 evolent-health-affirms-fy2025-sales-guidance-of-1850b-1880b-vs-1884b-est

Evolent Health (NYSE:EVH) affirms FY2025 sales outlook from $1.850 billion-$1.880 billion to $1.850 billion-$1.880 billion vs $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION